Guselkumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients: results of the phase III randomized placebo-controlled PROTOSTAR study
- PMID: 39708367
- DOI: 10.1093/bjd/ljae502
Guselkumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients: results of the phase III randomized placebo-controlled PROTOSTAR study
Abstract
Background: No currently approved treatment for paediatric plaque psoriasis selectively targets interleukin (IL)-23. In adults, guselkumab (a selective IL-23 inhibitor that targets the p19 subunit) demonstrated substantial efficacy with a favourable safety profile in treating moderate-to-severe plaque psoriasis.
Objectives: To evaluate the efficacy and safety of guselkumab in paediatric patients with moderate-to-severe plaque psoriasis (PROTOSTAR; NCT03451851).
Methods: This phase III randomized placebo-controlled study enrolled patients aged ≥ 6 to < 18 years with moderate-to-severe plaque psoriasis. In part 1 [week (W)0-W16], patients were randomized to receive guselkumab, placebo or open-label etanercept (active reference arm). At W16, part 1 patients entered a guselkumab withdrawal/retreatment period or continued/crossed over to receive guselkumab (W16-W52). Co-primary endpoints were Investigator Global Assessment (IGA) 0/1 and ≥ 75% improvement in Psoriasis Area and Severity Index (PASI 75) [or U.S. Food and Drug Administration-required ≥ 90% improvement in PASI (PASI 90) co-primary endpoint] responses at W16 of part 1. Part 2 evaluated continuous open-label guselkumab treatment (W0-W52).
Results: Of 92 and 28 patients enrolled in parts 1 and 2, respectively, 86% and 96% continued treatment through W52. In part 1, at W16, significantly higher proportions of guselkumab-treated compared with placebo-treated patients achieved IGA 0/1 (66% vs. 16%; P < 0.001), PASI 75 (76% vs. 20%; P < 0.001) and PASI 90 (56% vs. 16%; P < 0.01). More than one-third of guselkumab-treated patients achieved clear skin [IGA 0: 39% vs. 4% placebo; 100% improvement in PASI (PASI 100): 34% vs. 0% placebo; both P < 0.01]. In part 2, at W52, 86%, 93% and 82% of guselkumab-treated patients achieved IGA 0/1, PASI 75 and PASI 90, respectively. Through W16 of part 1, 42%, 68% and 58% of guselkumab-, placebo- and etanercept-treated patients, respectively, experienced adverse events (AEs). Rates of AEs with guselkumab were similar through W52 in parts 1 and 2; common AEs included nasopharyngitis, upper respiratory tract infection and COVID-19. No serious or opportunistic infections occurred.
Conclusions: Guselkumab demonstrated significant and clinically meaningful responses in paediatric patients with moderate-to-severe plaque psoriasis, and all co-primary and major secondary endpoints were met. Safety outcomes for guselkumab in paediatric patients were similar to placebo and consistent with the established profile in adults, with no new safety signals identified. These findings support the use of guselkumab to treat paediatric patients with moderate-to-severe plaque psoriasis.
Plain language summary
Worldwide, 2% to 3% of people have psoriasis. About a third of these people develop the disease before adulthood. A type of the disease called ‘plaque psoriasis’ is a chronic, inflammatory skin disease. It can be itchy and painful. A drug called ‘guselkumab’ can be used to treat adults with moderate-to-severe plaque psoriasis. In adults, guselkumab has been shown to improve plaque psoriasis, with side effects similar to those of a placebo (or ‘dummy’ drug). We wanted to find out if guselkumab is a safe and effective treatment for children and adolescents with moderate-to-severe plaque psoriasis. In study part 1, patients were randomly assigned to receive guselkumab or placebo for 16 weeks. After week 16, depending on their response to the treatment, patients were able to stop taking guselkumab, continue taking it or change from placebo to guselkumab. The goal of study part 1 was to compare the percentage of patients who achieved clear or almost clear skin with guselkumab at week 16 with the percentage of patients who achieved clear or almost clear skin with placebo at week 16. In study part 2, patients received guselkumab for up to 1 year. Ninety-two patients were enrolled in study part 1, and 28 were enrolled in study part 2. In study part 1, significantly more patients treated with guselkumab than patients given the placebo achieved clear or almost clear skin at week 16. In study part 2, more than 80% of patients had clear or almost clear skin after 1 year of guselkumab treatment. In both parts of the study, patients who took guselkumab and their families said they had an improved quality of life. In study part 1, at week 16, side effects were seen in 42% of patients who took guselkumab and in 68% of patients who took placebo. After 1 year of guselkumab treatment, the most common side effects in both parts of the study were infections that were not serious. The results suggest that guselkumab is a promising treatment for children and adolescents with moderate-to-severe plaque psoriasis.
© The Author(s) 2024. Published by Oxford University Press on behalf of British Association of Dermatologists.
Conflict of interest statement
Conflicts of interest: V.H.P. has served as an advisor, consultant and/or speaker for AbbVie, Actelion, Amgen, Apogee Therapeutics, Aralez, Arcutis, Aspen, Bausch Health, BioScript Solutions, Boehringer Ingelheim, Bristol Myers Squibb, Canadian Psoriasis Network, Celgene, Celltrion, Cipher, CorEvitas, Eli Lilly, Galderma, GlaxoSmithKline, Homeocan, Incyte, JAMP Pharma, Janssen, Johnson & Johnson, LEO Pharma, Medexus, Novartis, Organon, Pediapharm, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharma, Tribute, UCB and Valeant; has served as an investigator for AbbVie, AnaptysBio, Apogee Therapeutics, Arcutis, Arena, Asana, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Concert, CorEvitas, Dermavant, Dermira, Eli Lilly, Galderma, Incyte, Janssen, LEO Pharma, Nektar Therapeutics, Nimbus Lakshmi, Novartis, Pfizer, RAPT Therapeutics, Regeneron, Reistone, Sanofi Genzyme, Sun Pharma, Takeda, UCB and Vyne Therapeutics; and has received grants from AbbVie, Bausch Health, Janssen, LEO Pharma, Novartis and Sanofi Genzyme. M.M.B.S. has received grants from or has been involved in clinical trials with AbbVie, Amgen, Celgene, Eli Lilly, Janssen, LEO Pharma and Pfizer; and has served as a consultant for AbbVie, Eli Lilly, Janssen, LEO Pharma, Novartis, Pfizer and UCB (fees were paid directly to the institution). D.W.-T. has served as an advisor, speaker or investigator for AbbVie, Almirall, Amgen, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Hexal, Incyte, Janssen-Cilag, LEO Pharma, Eli Lilly, Medac, Merck Sharp & Dohme, MoonLake, Novartis, Pfizer and UCB Pharma. E.S. has served as a principal investigator for AbbVie, Janssen, Pfizer and Takeda. A.K. has served as a principal investigator for AbbVie, Bristol Myers Squibb, Eli Lilly, Galderma, Janssen, LEO Pharma, Novartis, Pfizer, Regeneron and UCB. B.v.H., M.J., G.J., S.L., C.M.C.D., V.S. and H.C. are employees of Janssen Research & Development, LLC, a wholly owned subsidiary of Johnson & Johnson; employees may own stock in Johnson & Johnson. A.S.P. has been an investigator for AbbVie, Applied Pharma Research, Biomendics, Dermavant, Eli Lilly, Incyte, Janssen, Krystal, Regeneron, Timber and UCB; a consultant for AbbVie, Abeona, Apogee, Arcutis, Aslan, BioCryst, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Incyte, Johnson and Johnson, Krystal Biotech, LEO Pharma, Mitsubishi Tanabe, Nektar, Primus, Procter & Gamble, Regeneron, Sanofi, Seanergy, TWI Biotech, and UCB; and has served on the Data Safety Monitoring Board for AbbVie, Abeona and Galderma.
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
